<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1. INDICATIONS AND USAGE<BR>               <BR>                  XALKORI is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. <BR>                  This indication is based on response rate. There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        XALKORI is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1) This indication is based on response rate. There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.<BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>